NIVO-ALTER Study: Assessing Nivolumab’s Altered Dosing in Non-Small Cell Lung Cancer
Indian Journal of Medical and Paediatric Oncology · 01.02.2026 · 47 (01) · A01-A58
DOI: 10.1055/s-0046-1818521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.02.2026. Verfasst von V. M. Chandrakanth und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
In countries with economic burdens, altered dose immunotherapy is increasingly used in cancer management. Low-dose Nivolumab in combination with oral metronomic therapy has demonstrated improved survival outcomes in recurrent/metastatic head and neck cancer. However, limited data are available on the use of altered-dose Nivolumab in lung cancer. Materials and Methods: Retrospectively analysis 96 patients with NSCLC, tested negative for EGFR and ALK mutations and had received at least one dose of Nivolumab. The standard dose (Std. D) of Nivolumab, administered at 3 mg/kg intravenously every 2 weeks, was compared with altered dose (Alt. D) included 100 mg biweekly (24%), 40 mg biweekly (35%), and 40 mg every 4 weeks (10%). The primary objective was to assess efficacy, including overall survival (OS), progression-free survival (PFS), and safety.
Results
The median age of the population is 62 years, with 91.7% being Males. ECOG score was 1 in 66.7% and 2 in 30.2%. The PFS in the SD group was 5.0 ± 0.9 months, and 3.0 ± 0.4 months in AD group. The PFS of SD versus AD was statistically significant ( p = 0.002). The SD and AD group's OS was 10.0 ± 1.4 and 5.0 ± 1.1 months, respectively. There was no statistical significance in the OS of SD versus AD (0.075). The SD showed a better RR at 49% compared to 39% in the AD group. Altered doses were associated with fewer adverse events. In the PDL-1 positive subgroup receiving second-line treatment, median OS and PFS changes were insignificant.
Conclusion
Among NSCLC patients in the second line and beyond, altered-dose Nivolumab resulted in shorter OS and PFS, though there was no change in the PDL-1-positive subgroup. Therefore, low-dose Nivolumab can be considered a less toxic and reasonably effective option for patients without access to standard doses, particularly in PDL-1-positive patients. Publication History Article published online: 20 February 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Zitieren
APA
Chandrakanth, V. M., Agarwala, V., Sardar, P., Nayak, H., Choudhary, N., Sharma, A., Carthikeyan, M. S., Basu, M., Mandal, K., Kumar, S., Nayak, H., & Sadhya, A. (2026). NIVO-ALTER Study: Assessing Nivolumab’s Altered Dosing in Non-Small Cell Lung Cancer. Indian Journal of Medical and Paediatric Oncology, 47(01), A01-A58. https://doi.org/10.1055/s-0046-1818521
Vancouver
Chandrakanth VM, Agarwala V, Sardar P, Nayak H, Choudhary N, Sharma A, et al. NIVO-ALTER Study: Assessing Nivolumab’s Altered Dosing in Non-Small Cell Lung Cancer. Indian Journal of Medical and Paediatric Oncology. 2026;47(01):A01-A58. doi:10.1055/s-0046-1818521
BibTeX
@article{Chandrakanth2026,
author = {Chandrakanth, V. M. and Agarwala, Vivek and Sardar, Pritam and Nayak, Himadri and Choudhary, Neha and Sharma, Amit and Carthikeyan, M. S. and Basu, Moinak and Mandal, Kaustav and Kumar, Subhabrata and Nayak, Himadri and Sadhya, Aparajita},
title = {NIVO-ALTER Study: Assessing Nivolumab’s Altered Dosing in Non-Small Cell Lung Cancer},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2026},
volume = {47},
number = {01},
pages = {A01--A58},
doi = {10.1055/s-0046-1818521}
}
EUVIMED